GlaxoSmithKline Pharmaceuticals Limited
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
2/10
|
56.38 | 45.74 | 23.26% | 79.7 | -29.26% |
| P/S |
|
9.66 | 5.12 | 88.62% |
|
|
| P/BV |
|
18.71 | 6.3 | 196.99% |
|
|
| P/FCF |
|
42.82 | 168.72 | -74.62% |
|
|
| Ev/Ebitda |
|
24.13 | 13.54 | 78.19% |
|
|
| Ev/S |
|
6.34 | 4.77 | 32.92% |
|
|
| Ev/FCF |
|
39.6 | 163.7 | -75.81% |
|
|
| E/P |
|
0.025 | 0.0451 | -44.58% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
8/10
|
26.26 | 20.29 | 29.47% | 22.4 | +17.24% |
| ROE |
|
33.53 | 17.11 | 95.93% |
|
|
| ROA |
|
17.14 | 10.34 | 65.86% |
|
|
| ROIC |
|
0 | 10.89 | -100% |
|
|
| ROS |
|
17.14 | 11.98 | 43.07% |
|
|
| ROCE |
|
0 | 4.26 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
0.0172 | 1.22 | -98.59% | 0.013 | +32.19% |
| Nеt Debt/Ebitda |
|
0 | 1.06 | -100% |
|
|
| Debt/Ratio |
|
0.0044 | 0.1307 | -96.66% |
|
|
| Debt/Equity |
|
0.0042 | 0.5459 | -99.23% |
|
|
| Debt/Net Income |
|
0.0263 | 3.19 | -99.17% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
4.5/10
|
1.8 | 11.92 | -84.9% | 3.28 | -45.1% |
| Number of years of dividend growth |
|
0 | 1.26 | -100% | ||
| DSI |
|
0.8571 | 0.8481 | 1.06% |
|
|
| Average dividend growth |
|
-126.39 | -63.67 | 98.5% |
|
|
| Average percentage for 5 years |
|
3.28 | 11.6 | -71.74% |
|
|
| Average percentage for payments |
|
148.6 | 30.57 | 386.08% |
|
|
| Difference from average difference in sector |
|
-10.12 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
1/10
|
6.74 | 80.84 | -91.66% | ||
| Growth impulse Ebitda in 5 years |
|
23.53 | 45.31 | -48.07% | ||
| Growth impulse Net Income in 5 years |
|
532.97 | 131.41 | 305.58% | ||
| Growth impulse FCF in 5 years |
|
64.61 | 76.02 | -15.01% | ||
| Growth impulse EPS in 5 years |
|
11.29 | 286.48 | -96.06% |
IP Score
5.59/10
